Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MGF | ISIN: US71902K3032 | Ticker-Symbol:
NASDAQ
24.04.25
17:18 Uhr
1,055 US-Dollar
+0,250
+31,12 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERO THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CERO THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur CERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:46CERo Therapeutics beginnt Phase-1-Studie für AML-Behandlung3
14:30CERo Therapeutics begins Phase 1 trial for AML treatment2
14:18CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia1
DiCERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs-
DiCERo Therapeutics announces up to $8M Series D financing; shares up2
DiCERo Therapeutics secures $8 million in funding for cancer therapy2
CERO THERAPEUTICS Aktie jetzt für 0€ handeln
DiCERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report-
DiCERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing1
DiBoral Capital sets Cero Therapeutics stock with Buy rating1
15.04.CERO THERAPEUTICS HOLDINGS, INC. - 10-K, Annual Report1
10.04.CERo Therapeutics erweitert Patentportfolio für Krebstherapie2
10.04.CERo Therapeutics erweitert Patentportfolio mit neuen US-Zulassungen1
10.04.CERo Therapeutics expands patent portfolio with new US approvals1
10.04.CERo Therapeutics expands patent portfolio for cancer therapy1
10.04.CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236272Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc....
► Artikel lesen
09.04.CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia152SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the...
► Artikel lesen
01.04.CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
31.03.CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors1
31.03.CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors96SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the...
► Artikel lesen
27.03.CERo Therapeutics gears up for clinical trial of cancer therapy1
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1